(NASDAQ: IMVT) Immunovant's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Immunovant's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMVT's revenue for 2025 to be $1,105,243,623, with the lowest IMVT revenue forecast at $1,105,243,623, and the highest IMVT revenue forecast at $1,105,243,623. On average, 7 Wall Street analysts forecast IMVT's revenue for 2026 to be $11,527,689,533, with the lowest IMVT revenue forecast at $983,633,407, and the highest IMVT revenue forecast at $21,576,006,045.
In 2027, IMVT is forecast to generate $55,701,256,495 in revenue, with the lowest revenue forecast at $15,967,697,403 and the highest revenue forecast at $91,188,773,831.